Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 106

Sort by

Sort Order Select

Journal Articles

Post-Marketing Surveillance of the Safety and Effectiveness of Emicizumab in Japanese Patients with Congenital Hemophilia A with Inhibitors

Midori Shima, Katsuyuki Fukutake, Masanori Matsumoto, Yoshihiko Sugimura, Chiaki Sugita, Lyu Ji, Mika Kawano, Tadashi Matsushita

Blood (2024) 144 (Supplement 1): 2583.

https://doi.org/10.1182/blood-2024-193353

Published: 2024

Journal Articles

Three-Year Interim Analysis Results of the AOZORA Study to Evaluate the Long-Term Safety and Joint Health in Children with Hemophilia A without Factor VIII Inhibitors Receiving Emicizumab

Midori Shima, Hideyuki Takedani, Kaoru Kitsukawa, Masashi Taki, Akira Ishiguro, Chiai Nagae, Azusa Nagao, Daisuke Nosaka, Yui Kyogoku, Hiroki Oki, Keisuke Iwasaki, Keiji Nogami

Blood (2023) 142 (Supplement 1): 3991.

https://doi.org/10.1182/blood-2023-173073

Published: 2023

Journal Articles

Activated Protein C-Catalyzed Inactivation Pathway Down-Regulates NXT007-Mediated Hemostatic Function

Yuto Nakajima, Kenichi Ogiwara, Takehisa Kitazawa, Midori Shima, Keiji Nogami

Blood (2022) 140 (Supplement 1): 5576–5577.

https://doi.org/10.1182/blood-2022-162928

Published: 2022

Journal Articles

ADAMTS13 Plays a Critical Role in Acetaminophen-Induced Acute Liver Injury in Mice, and Can be a Novel Therapeutic Option

Akihiro Sawa, Kohei Tatsumi, Yoko Takabayashi, Yu Onodera, Ayaka Kakiwaki, Satoshi Senzaki, Nobushiro Nishimura, Hiromasa Kawashima, Kiyomi Yoshimoto, Mitsuhiko Sugimoto, Midori Shima, Kenji Nishio

Blood (2022) 140 (Supplement 1): 5516–5517.

https://doi.org/10.1182/blood-2022-169891

Published: 2022

Journal Articles

AOZORA Study: Interim Analysis of Joint Health in Children with Hemophilia A, without FVIII Inhibitors, 3 Years after Initiating Emicizumab

Midori Shima, Hideyuki Takedani, Kaoru Kitsukawa, Masashi Taki, Akira Ishiguro, Azusa Nagao, Daisuke Nosaka, Yui Kyogoku, Keisuke Iwasaki, Keiji Nogami

Blood (2022) 140 (Supplement 1): 2742–2744.

https://doi.org/10.1182/blood-2022-157249

Published: 2022

Journal Articles

Efficacy and Safety of Personalized Prophylaxis with Simoctocog Alfa in Adult Japanese Previously Treated Patients with Severe Hemophilia a

Midori Shima, Masashi Taki, Rie Shirayama, Tadashi Matsushita, Yasuharu Nishida, Azusa Nagao, Yoshiyuki Ogawa, Kazuo Kawasugi

Blood (2022) 140 (Supplement 1): 11304–11305.

https://doi.org/10.1182/blood-2022-167449

Published: 2022

Journal Articles

Efficacy and Safety of Emicizumab Prophylaxis in Patients with Acquired Hemophilia a Who Were Deemed Ineligible for Immunosuppressive Therapy: Additional Data from the Ageha Study

Hidekazu Nishikii, Nobuaki Suzuki, Ryota Kobayashi, Narumi Mizuno, Ryoto Ozaki, Midori Shima

Blood (2022) 140 (Supplement 1): 2724–2725.

https://doi.org/10.1182/blood-2022-162237

Published: 2022

Journal Articles

Escaping Ability of Human-Porcine Hybrid Factor VIII from Anti-Factor VIII Inhibitors with an A2 or C2 Epitope

Kuniyoshi Mizumachi, Yuto Nakajima, Naruto Shimonishi, Shoko Furukawa, Kenichi Ogiwara, Masahiro Takeyama, Midori Shima, Keiji Nogami

Blood (2022) 140 (Supplement 1): 8430–8431.

https://doi.org/10.1182/blood-2022-165714

Published: 2022

Journal Articles

Global Coagulation Potentials and Breakthrough Bleeds in Emicizumab-Treated Hemophilia a Patients Were Similar to Mild Hemophilia a Patients

Yuto Nakajima, Kuniyoshi Mizumachi, Naruto Shimonishi, Shoko Furukawa, Kenichi Ogiwara, Masahiro Takeyama, Midori Shima, Keiji Nogami

Blood (2021) 138 (Supplement 1): 2100.

https://doi.org/10.1182/blood-2021-146337

Published: 2021

Journal Articles

A Healthy Volunteer-Derived, Factor VIII-Neutralized, Acquired Hemophilia a-Mimetic Plasma Produces Similar Pharmacodynamic Responses of Emicizumab to Those in Patients with Congenital Hemophilia a with or without Inhibitors

Koichiro Yoneyama, Kazuo Tokuda, Tetsuhiro Soeda, Tomohisa Saito, Midori Shima

Blood (2021) 138 (Supplement 1): 3190.

https://doi.org/10.1182/blood-2021-144549

Published: 2021

Journal Articles

Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies

Blood (2021) 137 (16): 2231–2242.

https://doi.org/10.1182/blood.2020009217

Published: 2021

Includes: Supplemental data

Journal Articles

Safety and Efficacy of Emicizumab in Persons with Hemophilia a with or without FVIII Inhibitors: Pooled Data from Four Phase III Studies (HAVEN 1-4)

Blood (2020) 136 (Supplement 1): 3–5.

https://doi.org/10.1182/blood-2020-137438

Published: 2020

Journal Articles

An Investigational Dosing Algorithm of Emicizumab for Prophylaxis in Acquired Hemophilia a

Midori Shima, MD, Sayaka Nagami, BSc, Koichiro Yoneyama, MSc, Akira Nomura, MSc, Yoshiyuki Ogawa, MD PhD, Kagehiro Amano, MD PhD, Keiji Nogami, MDPhD

Blood (2020) 136 (Supplement 1): 26–27.

https://doi.org/10.1182/blood-2020-136488

Published: 2020

Journal Articles

A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors

Guy Young, Ri Liesner, Tiffany Chang, Robert Sidonio, Jr, Johannes Oldenburg, Victor Jiménez-Yuste, Johnny Mahlangu, Rebecca Kruse-Jarres, Michael Wang, Marianne Uguen, Michelle Y. Doral, Lilyan Y. Wright, Christophe Schmitt, Gallia G. Levy, Midori Shima, Maria Elisa Mancuso

Blood (2019) 134 (24): 2127–2138.

https://doi.org/10.1182/blood.2019001869

Published: 2019

Includes: Supplemental data

Journal Articles

Residues 1680-1684 in the A3 Domain of Factor VIII Contain a Novel Thrombin-Interactive Site Responsible for Proteolytic Cleavage at Arg 1689

Yuto Nakajima, MD, Keiji Nogami, MD PhD, Hiroaki Minami, MD, Kana Sasai, Midori Shima, MD PhD

Blood (2019) 134 (Supplement_1): 1107.

https://doi.org/10.1182/blood-2019-129313

Published: 2019

Journal Articles

New therapies using nonfactor products for patients with hemophilia and inhibitors

Keiji Nogami, Midori Shima

Blood (2019) 133 (5): 399–406.

https://doi.org/10.1182/blood-2018-07-820712

Published: 2019

Journal Articles

Pre-Analysis for Hemostatic Effect of Bypassing Agents in Hemophilia a Patients with Inhibitors Under the Emicizumab Prophylaxis By Global Assays

Shoko Furukawa, MD, Keiji Nogami, MD PhD, Tomoko Matsumoto, PhD, Ryu Kasai, MSc, Midori Shima, MD PhD

Blood (2018) 132 (Supplement 1): 3793.

https://doi.org/10.1182/blood-2018-99-114355

Published: 2018

Journal Articles

Untreated Bleeds May Be Historically Under-Reported and More Prevalent in People with Hemophilia A with Inhibitors: An Examination of Bleed Data from a Prospective, Non-Interventional Study

Michael U. Callaghan, MD, Elina Asikanius, Michaela Lehle, Johannes Oldenburg, Johnny Mahlangu, Marianne Uguen, Sammy Chebon, Rebecca Kruse-Jarres, Victor Jimenez-Yuste, Midori Shima, MD PhD, Peter Trask, Christine L. Kempton, Craig M. Kessler, Gallia G. Levy, Elena Santagostino

Blood (2018) 132 (Supplement 1): 383.

https://doi.org/10.1182/blood-2018-99-118160

Published: 2018

Journal Articles

Coagulation and Fibrinolysis Imbalance Demonstrated By Novel Simultaneous Thrombin and Plasmin Generation Assay during L-Asparaginase Treatment Phase of Induction Therapy in Pediatric Acute Lymphoblastic Leukemia

Takashi Ishihara, MD, Keiji Nogami, MD PhD, Satoshi Ochi, MD, Toshiaki Ishida, MD PhD, Yoshiyuki Kosaka, MD PhD, Akihisa Sawada, MD PhD, Masami Inoue, MD, Shinya Osone, MD PhD, Toshihiko Imamura, MD PhD, Hajime Hosoi, MD PhD, Midori Shima, MD PhD

Blood (2018) 132 (Supplement 1): 3972.

https://doi.org/10.1182/blood-2018-99-110411

Published: 2018

Journal Articles

Emicizumab Prophylaxis Provides Flexible and Effective Bleed Control in Children with Hemophilia Α with Inhibitors: Results from the HAVEN 2 Study

Guy Young, Ri Liesner, Robert F. Sidonio, Jr., Johannes Oldenburg, Victor Jimenez-Yuste, Johnny Mahlangu, Rebecca Kruse-Jarres, Michael Wang, Tiffany Chang, Marianne Uguen, Michelle Doral, Christophe Schmitt, Gallia G. Levy, Midori Shima, MD PhD, Maria Elisa Mancuso

Blood (2018) 132 (Supplement 1): 632.

https://doi.org/10.1182/blood-2018-99-118153

Published: 2018

NARROW

Post-Marketing Surveillance of the Safety and Effectiveness of Emicizumab in Japanese Patients with Congenital Hemophilia A with Inhibitors

Three-Year Interim Analysis Results of the AOZORA Study to Evaluate the Long-Term Safety and Joint Health in Children with Hemophilia A without Factor VIII Inhibitors Receiving Emicizumab

Activated Protein C-Catalyzed Inactivation Pathway Down-Regulates NXT007-Mediated Hemostatic Function

ADAMTS13 Plays a Critical Role in Acetaminophen-Induced Acute Liver Injury in Mice, and Can be a Novel Therapeutic Option

AOZORA Study: Interim Analysis of Joint Health in Children with Hemophilia A, without FVIII Inhibitors, 3 Years after Initiating Emicizumab

Efficacy and Safety of Personalized Prophylaxis with Simoctocog Alfa in Adult Japanese Previously Treated Patients with Severe Hemophilia a

Efficacy and Safety of Emicizumab Prophylaxis in Patients with Acquired Hemophilia a Who Were Deemed Ineligible for Immunosuppressive Therapy: Additional Data from the Ageha Study

Escaping Ability of Human-Porcine Hybrid Factor VIII from Anti-Factor VIII Inhibitors with an A2 or C2 Epitope

Global Coagulation Potentials and Breakthrough Bleeds in Emicizumab-Treated Hemophilia a Patients Were Similar to Mild Hemophilia a Patients

A Healthy Volunteer-Derived, Factor VIII-Neutralized, Acquired Hemophilia a-Mimetic Plasma Produces Similar Pharmacodynamic Responses of Emicizumab to Those in Patients with Congenital Hemophilia a with or without Inhibitors

Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies

Safety and Efficacy of Emicizumab in Persons with Hemophilia a with or without FVIII Inhibitors: Pooled Data from Four Phase III Studies (HAVEN 1-4)

An Investigational Dosing Algorithm of Emicizumab for Prophylaxis in Acquired Hemophilia a

A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors

Residues 1680-1684 in the A3 Domain of Factor VIII Contain a Novel Thrombin-Interactive Site Responsible for Proteolytic Cleavage at Arg 1689

New therapies using nonfactor products for patients with hemophilia and inhibitors

Pre-Analysis for Hemostatic Effect of Bypassing Agents in Hemophilia a Patients with Inhibitors Under the Emicizumab Prophylaxis By Global Assays

Untreated Bleeds May Be Historically Under-Reported and More Prevalent in People with Hemophilia A with Inhibitors: An Examination of Bleed Data from a Prospective, Non-Interventional Study

Coagulation and Fibrinolysis Imbalance Demonstrated By Novel Simultaneous Thrombin and Plasmin Generation Assay during L-Asparaginase Treatment Phase of Induction Therapy in Pediatric Acute Lymphoblastic Leukemia

Emicizumab Prophylaxis Provides Flexible and Effective Bleed Control in Children with Hemophilia Α with Inhibitors: Results from the HAVEN 2 Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only